Clinical trials: Depressive Disorder NOS
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Major Depressive Disorder
Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression
Major depressive disorder (MDD) is the leading cause of disability in the developed world and is associated with lost productivity, increased health care utilization, and mortality.
- Trial name
- NCT02176408
- Testing
- Behavioral Activation, Exercise Intervention, Stretching Intervention
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Boston University Charles River Campus
Depressive Disorder, Major
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition)…
- Trial name
- NCT02709746
- Testing
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day
- Where
- 124 sites in United States, Bulgaria and 17 more
- Volunteers
- 784 people
- Sponsor
- H. Lundbeck A/S
Major Depression
A Family-based Primary Care Intervention to Enhance Older Men's Depression Care
Despite the public health importance of clinical depression, more than 50% of depressed adults receive inadequate or no treatment, with even higher rates of under-treatment in men and minorities.
- Trial name
- NCT02143024
- Testing
- Family-based depression intervention, Usual care plus educational materials
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, Davis
Premenstrual Dysphoric Disorder
Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study
This research study will look at brain and symptom differences among women with severe premenstrual mood symptoms. One goal of this study is to look at the effects of taking a nasal spray containing oxytocin (a hormone made in…
- Trial name
- NCT02508103
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Depressive Disorder, Major
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
This is a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study to confirm the efficacy of 323U66 Sustained Release (SR) orally administered to patients with MDD (Major Depressive Disorder) at…
- Trial name
- NCT01138007
- Testing
- 323U66 SR 150 mg tablet
- Where
- 59 sites in Japan, South Korea
- Volunteers
- 572 people
- Sponsor
- GlaxoSmithKline
Dysthymic Disorder
Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase.
- Trial name
- NCT00220701
- Testing
- Lexapro (escitalopram)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Major Depressive Disorder
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
This is a phase 3, flexible-dose, open-label, multi-center study. The subjects who complete the week 8 visit in the prior double-blind study (B2411263) will be eligible to participate in this study.
- Trial name
- NCT01485887
- Testing
- Venlafaxine ER
- Where
- 25 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder, Major
A Study of LY2216684 in Participants With Impaired Hepatic Function
The purpose of this study is to evaluate the effect of liver function on how much of the study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT01241435
- Testing
- LY2216684
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home
The current use of telepsychiatry, or psychiatric care using videoconferencing, is very limited. The present study investigates the use of this method with a depressed Chinese American population in a nursing home.
- Trial name
- NCT00505518
- Testing
- Psychotropic medication (at discretion of psychiatrist), Collaborative psychiatric and primary medical care
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Dysthymia
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
- Trial name
- NCT01189812
- Testing
- Lithium Carbonate, Citalopram
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Columbia Northwest Pharmaceuticals
Major Depressive Disorder
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect…
- Trial name
- NCT01263093
- Testing
- Clopidogrel, LY2216684
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of sirukumab as adjunctive treatment to antidepressant therapy (monoaminergic antidepressant) where sirukumab (administered as a 50 milligram (mg) subcutaneous (SC) injection…
- Trial name
- NCT02473289
- Testing
- Sirukumab 50 mg
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 193 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture
This will be a randomized, single blind study of 6 weeks duration involving the use of auricular acupuncture or sham acupuncture in the adjunctive treatment of depression in college students.
- Trial name
- NCT02579343
- Testing
- Auricular Acupuncture
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Florida Gulf Coast University
Depressive Disorder, Major, Bipolar Disorder
In-person vs. Remote Wellness Support
The study team will use components of the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework to compare Cognitive Adaptation Training (CAT) to Remotely delivered Cognitive Adaptation Training (R-CAT)…
- Conditions
- Depressive Disorder, Major, Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
- Trial name
- R-CAT (NCT04526067)
- Testing
- CAT, R-CAT
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal…
- Trial name
- TRANSFORM-1 (NCT02417064)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 90 sites in United States, Belgium and 7 more
- Volunteers
- 346 people
- Sponsor
- Janssen Research & Development, LLC
Major Depression
Motivational Interviews for Depression in Primary Care
The purpose of the study is to determine whether motivational interviewing with guideline-based medical management for depression will significantly improve time to depression recovery and increase the proportion of subjects in…
- Trial name
- NCT01114334
- Testing
- Guideline-Based Medical Management, Motivational Interviewing for Depression
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Denver Health and Hospital Authority
Treatment Resistant Depression
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant…
- Trial name
- NCT04663321
- Testing
- MK-1942
- Where
- 45 sites in United States
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Postpartum Depression
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum…
- Trial name
- NCT02942004
- Testing
- SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 138 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder, Cognitive Behavior Therapy
Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework
The primary goal of the pilot is to test the feasibility and utility of using a text-messaging system to engage adolescents in improved homework adherence during cognitive-behavioral therapy (CBT) for major depressive disorder.
- Conditions
- Major Depressive Disorder, Cognitive Behavior Therapy, Text Messaging
- Trial name
- NCT00919932
- Testing
- Paper and pen homework, Text message system homework.
- Volunteers
- 9 people
- Sponsor
- University of Pittsburgh